What question did this study set out to answer?

To determine whether a retrovirus-mediated AT1R antisense gene delivery system (LNSV-AT1R-AS) provides long-term blood pressure control compared with daily losartan administration in spontaneously hypertensive rats.

September 1, 1997Hypertension

Losartan Versus Gene Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

Does LNSV-AT1R-AS gene therapy improve long-term blood pressure control compared to losartan in spontaneously hypertensive rats?

Population

5-day-old Wistar-Kyoto rats and spontaneously hypertensive rats (SHR)

Comparison

Retroviral-mediated AT1R antisense cDNA gene… vs Losartan

Design

Preclinical

Follow-up

up to 90 days

Authors

DLDi LuCapital Medical University MRMohan K. RaizadaPreventive Cardiology SIShridhar N. IyerAlbany Medical Center Hospital

Discussion

Member takes

Implication

Hypothesis-generating for durable gene therapy in hypertension; leaves open human translation and safety.

Key Points

To determine whether a retrovirus-mediated AT1R antisense gene delivery system (LNSV-AT1R-AS) provides long-term blood pressure control compared with daily losartan administration in spontaneously hypertensive rats.
Administered retroviral-mediated AT1R antisense cDNA (LNSV-AT1R-AS) into 5-day-old Wistar-Kyoto rats and spontaneously hypertensive rats (SHR).
Assessed antisense expression duration, baseline blood pressure changes, and Angiotensin II pressor and dipsogenic responses relative to daily losartan treatment.
LNSV-AT1R-AS expression was detected within 3 days, persisted for at least 30 days, and selectively reduced basal blood pressure in SHR by 25 to 30 mm Hg.
A single genetic treatment maintained blood pressure reduction for 90 days in SHR, whereas the antihypertensive effect of losartan lasted less than 24 hours.
Angiotensin II pressor and dipsogenic responses were attenuated in both rat strains, and losartan failed to produce any additive blood pressure lowering in LNSV-AT1R-AS-treated SHR.

Structured PICO

Does LNSV-AT1R-AS gene therapy improve long-term blood pressure control compared to losartan in spontaneously hypertensive rats?

Population

5-day-old Wistar-Kyoto rats and spontaneously hypertensive rats (SHR)

Intervention

Retroviral-mediated AT1R antisense cDNA gene delivery system (LNSV-AT1R-AS)

Comparator

Losartan

Outcome

Blood pressure lowering effects and duration of antihypertensive effectsurrogate

A single genetic treatment with AT1R antisense cDNA provides long-term blood pressure control comparable to daily losartan in spontaneously hypertensive rats.

Cite This Study

Lu et al. (1997) studied this question.

synapsesocial.com/papers/6a70d66535aa2c282ce22945 https://doi.org/10.1161/01.hyp.30.3.363

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Losartan Versus Gene Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Losartan Versus Gene Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider